TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06662422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System
Description: The Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System is a single-use electrode placed on and around the ear which provides transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System
Description: The Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System is a single-use electrode placed on and around the ear which provides transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN).
Study: NCT06665789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: An 8-week Mindfulness-based stress reduction training programme
Study: NCT06588400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AOSEPT Plus and AOCup lens case
Description: Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AOSEPT Plus with HydraGlyde and AOCup lens case
Description: Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus with HydraGlyde) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Daily wear, reusable, soft (including hydrogel and silicone hydrogel) or rigid gas permeable (RGP) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Daily wear, reusable, soft (including hydrogel and silicone hydrogel) or rigid gas permeable (RGP) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
Study: NCT06612281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: colorectal cancer (CRC) screening
Description: Gixam test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: colorectal cancer screening
Description: Fecal Immunochemistry Test (FIT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy after bowel cleansing
Description: Standard of care optical colonoscopy for colorectal cancer screening
Study: NCT05154214

Intervention type: PROCEDURE
Intervention: Drug-induced sleep endoscopy directed surgery
Description: Surgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep
Study: NCT06224543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SubtleGAD
Description: SubtleGAD is an image processing software developed to enhance MR images acquired with low dose gadobutrol.
Study: NCT06668467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: An 4-week Mindfulness-based stress reduction training programme
Study: NCT06616766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH42946
Description: YH42946
Study: NCT06521853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK With Autogenous Bone Graft
Description: placement of PEEK With Autogenous Bone Graft

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK With Xenograft
Description: placement of PEEK With xenograft
Study: NCT06674772

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva test
Description: Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva test
Description: Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.
Study: NCT06779812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Surgery
Description: Carpal tunnel surgery is performed endoscopically, using smaller incisions. Endoscopic surgery is a minimally invasive method that allows for faster and less painful recovery

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Carpal Tunnel Surgery
Description: Carpal tunnel surgery is performed endoscopically, using smaller incisions. Endoscopic surgery is a minimally invasive method that allows for faster and less painful recovery
Study: NCT06586957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKT3964
Description: Oral CDK2 Degrader

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKT3964
Description: Oral CDK2 Degrader
Study: NCT06224543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SubtleGAD
Description: SubtleGAD is an image processing software developed to enhance MR images acquired with low dose gadobutrol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadobutrol
Description: Gadavist is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadobutrol
Description: Gadavist is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
Study: NCT06051695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A2B694
Description: Autologous logic-gated Tmod CAR T cells

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: xT CDx with HLA-LOH Assay
Description: An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
Study: NCT05736731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A2B530
Description: Autologous logic-gated Tmod CAR T-cells

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: xT-Onco with HLA-LOH Assay
Description: An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
Study: NCT05911958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 for injection
Description: SHR-A1811 for injection
Study: NCT06271499

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery catheterization with USG
Description: Radial artery catheterization with USG The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with the high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery catheterization with smart glasses integrated UGG
Description: The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). Before the study, as practitioners had no previous experience with smart glasses, they performed 5 catheterizations with smart glasses integrated USG on model. The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with smart glasses integrated high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
Study: NCT06678997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zinc-L carnosine/Polaprezinc
Description: This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thickened formula
Description: This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
Study: NCT06546735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N0728
Description: 1 tablet of the test drug (N0728) and 1 tablet of placebo of Vesomni®.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vesomni®
Description: 1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.
Study: NCT06779812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real auricolothery
Description: 3 days before the intervention, patients will have an auriculotherapy session with an experimental group

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham auriculotherapy
Description: 3 days before the intervention, patients will have an auriculotherapy session with an sham group
Study: NCT06781034

Intervention type: OTHER
Intervention: None, pure observational study
Description: None, pure observational study
Study: NCT06781346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal Block
Description: In RI block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the medial border of the scapula between the 4th and 5th rib of the patients in the RIB group. In the ultrasound image, the trapezius muscle, rhomboid muscle, intercostal muscles,pleura, and lung were identified. Under the aseptic condition, inserted laterally in the plane of the T5 level guided by an ultrasound probe with an in plane technique. The intravascular injection should be confirmed negative through aspiration, and 1-3 ml of normal saline was injected to divide the rhomboid and intercostal muscle, and a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected After negative aspiration of blood or air, injected into the deep layer of the rhomboid muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: In the TPV block group , the transverse process and the pleura will be identified and needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards.
Study: NCT05244928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The team training program Team Strategies and Tools to Enhance Performance and Patient Safety®
Description: Team Strategies and Tools to Enhance Performance and Patient Safety® is a team training program consisting of an evidence-based set of tools designed to develop teamwork skills with the goal of improving quality in healthcare services and providing safer patient care. In this study, selected tools from the Team Strategies and Tools to Enhance Performance and Patient Safety® curriculum have been chosen for implementation over a 4-month period together with a general emphasis on the key principles: communication, leadership, situation monitoring and mutual support. A full day introduction will be held to mark the start of the intervention and each successive month will have a focus on a single key principle with associated tools.~A stepped wedge cluster randomized controlled trial provides the framework for the intervention of the team training program in two clusters including seven ambulance stations, in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The team training program Team Strategies and Tools to Enhance Performance and Patient Safety®
Description: Team Strategies and Tools to Enhance Performance and Patient Safety® is a team training program consisting of an evidence-based set of tools designed to develop teamwork skills with the goal of improving quality in healthcare services and providing safer patient care. In this study, selected tools from the Team Strategies and Tools to Enhance Performance and Patient Safety® curriculum have been chosen for implementation over a 4-month period together with a general emphasis on the key principles: communication, leadership, situation monitoring and mutual support. A full day introduction will be held to mark the start of the intervention and each successive month will have a focus on a single key principle with associated tools.~A stepped wedge cluster randomized controlled trial provides the framework for the intervention of the team training program in two clusters including seven ambulance stations, in total.
Study: NCT06062615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement using Omnibot Knee System
Description: total knee replacement with robotic assistance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Total knee replacement
Description: Conventional total knee replacement without robotic assistance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnibot Robotic Knee System
Description: utilizes an active motorized knee spacer to measure ligament tension and gap balance after the tibia has been cut during surgery
Study: NCT04943822

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: A new APP
Description: A new APP for prevention and treatment of complications of intestinal peristomal skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A new APP
Description: A new APP for prevention and treatment of complications of intestinal peristomal skin
Study: NCT05860777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complexity score and implementation
Description: AI machine learning model to identify patients with complex care needs and implementation with active reaching out to clinicians to offer interpreter services
Study: NCT04619225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TetraGraph
Description: FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
Study: NCT06182293

Intervention type: OTHER
Group type: OTHER
Intervention: Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota
Description: Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.

Intervention type: OTHER
Group type: OTHER
Intervention: Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota
Description: Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.
Study: NCT05285865

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Thrice a day for complete length of stay. This is Conventional treatment The total duration of session will be of 15-20 mins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Mobilization
Description: Thrice a day for complete length of stay including two sets of repetitions with a rest interval of 30 seconds between sets. Grade 1-3 As reported in a study Scapular mobilization (SM) i.e., Scapular superior, inferior glides, upward and downward rotations and scapular distraction, along with Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
Study: NCT06485557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab plus platinum-based chemotherapy
Description: The subjects in group A will receive 3 cycles of sintilimab plus platinum-based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab plus platinum-based chemotherapy
Description: The subjects in group B will receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab
Study: NCT06781723

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will perform leg press and leg extension immediately prior to ingestion of rice and beans or isolated mixture.
Study: NCT06485557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab plus platinum-based chemotherapy
Description: The subjects in group C will receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab.
Study: NCT06781723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform leg press and leg extension immediately prior to ingestion of rice and beans or isolated mixture.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isolated Mixture
Description: Participants will ingest isolated mixture of crystalized amino acids, maltodextrin, fiber and oil immediately after resistance exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice and Beans
Description: Participants will ingest cooked rice and beans meal immediately after resistance exercise.
Study: NCT06781372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Development and characterization of PDOs
Description: An amount of tissue of approximately 2-3 cm3, if available, will be allocated to the study. The specimen will be divided in three parts (depending on the volume of the biopsy) and used to: a) obtain PDOs according to established procedures (Chadwick, et al., 2020; Gamboa, et al., 2021); b) flash-frozen for molecular analysis of original tissue; c) used to isolate GSCs by flow-cytometry cell sorting. Only PDOs characterized by histological and molecular conformity with primary tumors will be used. The mutational status of genes frequently associated with GBM onset and progression will be analyzed in PDOs, and compared with data derived from tumor DNA, in order to assess their representation of the genetic heterogeneity of original tumors. These studies will allow us the set up a reliable procedure for the ex-vivo establishment of pre-clinical models of GBM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs
Description: PDOs and GSCs representing different GBM molecular subtypes will be treated with epigenetic modulators , with spliceosome inhibitors or with drugs that indirectly target the splicing machinery, such as PRMT5 inhibitors. These drugs will be tested for their ability to suppress growth and/or induce cell death, when administered either alone or in combination with standard chemotherapy. Furthermore, we will perform RNA sequencing experiments to identify TE-derived transcripts and splice variants induced by the treatments. By employing a computational pipeline developed in our laboratory (Pieraccioli and Sette, unpublished), we will also characterize the affinity for MHC-I and immunogenicity of neoepitopes encoded by the treatment-induced TE-derived transcripts and splice variants. The results of these analysis will allow to identify neoepitopes to be used for designing immunotherapy approaches.
Study: NCT05394519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide administered subcutaneously (s.c., under the skin) once-weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cagrilintide
Description: Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo semaglutide
Description: Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly
Study: NCT05799924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: The transcutaneous electrical acupoint stimulator applied alternating current (including sine wave, pulse wave and modulation wave) with frequency of 2 \~ 100Hz and intensity of 10-20mA to stimulate corresponding acupoints through skin electrodes. The stimulated acupoints include Hegu acupoints, Luogong acupoints, Neiguan acupoints and Waiguan acupoints.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non steroidal anti inflammatory drugs
Description: Hormonal contraception can suppress ovulation, NSAIDS can ease pain